There are 3161 resources available
1379P - c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study
Presenter: Jair Bar
Session: Poster session 06
1380P - PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
Presenter: Joseph Ciccolini
Session: Poster session 06
1381P - Comparison between standard dose 75mg/m<sup>2</sup> and fixed dose at 50mg of cisplatin in the treatment of non-small cell lung cancer patients in term of response rate and toxicity profile
Presenter: Maher Salamoon
Session: Poster session 06
1382P - Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
Presenter: Maurice Pérol
Session: Poster session 06
1383P - Distribution of actionable genetic variants in different sample types of Chinese NSCLC: A large real-world data based study
Presenter: Dongmei Lin
Session: Poster session 06
1384P - Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Yuki Sato
Session: Poster session 06
1385P - Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma
Presenter: Mariana Mancini
Session: Poster session 06
1386P - Prognostic value of EGFR A859S alteration in advanced NSCLC patients treated with third-generation EGFR-TKI
Presenter: Wei Xin Zhao
Session: Poster session 06
1387P - Real-world data, tolerability and clinical outcomes in patients with advanced NSCLC treated with sotorasib in the UK
Presenter: Rubab Batool
Session: Poster session 06
1388P - Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster session 06
Resources:
Abstract